Live Events | Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
In this Q&A, Zachary Feuer, MD, discusses the implementation of a telehealth-based rapid access program for evaluating men with an elevated PSA. Timothy D. McClure, MD, discusses 2-year PRESERVE trial ...
A recap of the FDA submissions and regulatory decisions in urology from June 2026. Welcome to Urology Times’® monthly FDA update! June 2026 brought a wave of regulatory developments across the urology ...
The following FAQs highlight key recommendations and practical takeaways from the 2026 AUA/SUO Advanced Prostate Cancer Guideline. Two overarching themes define the 2026 amendment: the consolidation ...
A comprehensive guide to the practice-changing, paradigm-shifting studies across benign urologic conditions. At the 2026 Annual Meeting of the American Urological Association in Washington, DC, the P2 ...
Isaac Y. Kim, MD, PhD, MBA, reflects on concerning trends in prostate cancer mortality, emphasizing how advances in diagnostics, treatment, and artificial intelligence may improve outcomes in the ...
Pre-operative counseling should frame vasectomy as intended permanent contraception, individualized to reproductive goals, and can be delivered virtually or in person while directly addressing ...
VYBRIQUE is a sildenafil oral film formulated for discreet, water-free administration, aiming to reduce use barriers for patients for whom privacy and convenience influence ED treatment adherence. A ...
Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer. The trial showed consistent benefits across clinical endpoints, ...
Zenflow's Spring Scope, a single-use cystoscope, received FDA 510(k) clearance, featuring a 12 French working channel for improved visualization. The Zenflow Spring System showed a 46% improvement in ...
Sunobinop showed significant symptom improvement in 41% of IC/BPS patients versus 9% with placebo, indicating its potential efficacy. The investigational compound targets the NOP receptor, affecting ...
"Based on this proposal, some shifts may significantly impact the practice of urology," write Jonathan Rubenstein, MD, and Mark Painter. On July 14, 2025, the Centers for Medicare & Medicaid Services ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results